[
  {
    "ts": null,
    "headline": "Reasons to Hold HealthEquity Stock in Your Portfolio for Now",
    "summary": "HQY rides on strong HSA growth, AI-driven efficiency gains and solid Q3 results, though data security threats remain a key risk.",
    "url": "https://finnhub.io/api/news?id=9782647f7110da7a9c17978b17b24d549ffed4e89bf6d8b933105d42534d25e8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767196320,
      "headline": "Reasons to Hold HealthEquity Stock in Your Portfolio for Now",
      "id": 137950435,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "HQY rides on strong HSA growth, AI-driven efficiency gains and solid Q3 results, though data security threats remain a key risk.",
      "url": "https://finnhub.io/api/news?id=9782647f7110da7a9c17978b17b24d549ffed4e89bf6d8b933105d42534d25e8"
    }
  },
  {
    "ts": null,
    "headline": "CODX Shares Dip Despite Australian Patent Grant for Co-Dx PCR Platform",
    "summary": "CoDiagnostics secures its first patent for the Co-Dx PCR platform in Australia, strengthening IP protection as the point-of-care system awaits regulatory clearance.",
    "url": "https://finnhub.io/api/news?id=08a3cbbbce54c30b3b8f2f29d2cfb0d48bc7261574d58cfccf96a75ae9ebb2e8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767196140,
      "headline": "CODX Shares Dip Despite Australian Patent Grant for Co-Dx PCR Platform",
      "id": 137950436,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "CoDiagnostics secures its first patent for the Co-Dx PCR platform in Australia, strengthening IP protection as the point-of-care system awaits regulatory clearance.",
      "url": "https://finnhub.io/api/news?id=08a3cbbbce54c30b3b8f2f29d2cfb0d48bc7261574d58cfccf96a75ae9ebb2e8"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why You Should Retain CONMED Stock in Your Portfolio Now",
    "summary": "CONMED gains momentum from high-margin platforms and supply-chain recovery, even as tariffs and dV5 adoption weigh on near-term margins.",
    "url": "https://finnhub.io/api/news?id=1657ecbf194d6d960a995b5807192e74cef9b40c326a44912fd6df0cd71ea0b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767184260,
      "headline": "Here's Why You Should Retain CONMED Stock in Your Portfolio Now",
      "id": 137950437,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "CONMED gains momentum from high-margin platforms and supply-chain recovery, even as tariffs and dV5 adoption weigh on near-term margins.",
      "url": "https://finnhub.io/api/news?id=1657ecbf194d6d960a995b5807192e74cef9b40c326a44912fd6df0cd71ea0b7"
    }
  },
  {
    "ts": null,
    "headline": "How Is Boston Scientific's Cardiovascular Growth Path Shaping Up?",
    "summary": "BSX's $50B cardiovascular business aims to outpace market growth across EP, WATCHMAN, ICTx and more.",
    "url": "https://finnhub.io/api/news?id=f03f64d6bf473144f8194e24d3e645b083a2da582c0bb1af1885b42b359499f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767183660,
      "headline": "How Is Boston Scientific's Cardiovascular Growth Path Shaping Up?",
      "id": 137950178,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "BSX's $50B cardiovascular business aims to outpace market growth across EP, WATCHMAN, ICTx and more.",
      "url": "https://finnhub.io/api/news?id=f03f64d6bf473144f8194e24d3e645b083a2da582c0bb1af1885b42b359499f8"
    }
  }
]